Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
Completed
Sanofi
Phase 3
2005-04-01
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and
effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with
type 1 diabetes mellitus.
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
Completed
Sanofi
Phase 3
2004-08-01
The purpose of this study is to show the non-inferiority of insulin glulisine administered
with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c
(HbA1c), from baseline to study week 24.
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
Completed
Sanofi
Phase 3
2004-08-01
The purpose of this study is to compare the change in weight from baseline to study week 52
in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal
Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.
Insulin Glulisine in Healthy Lean and Obese Subjects
Completed
Sanofi
Phase 1
2004-04-01
Primary objective
- To investigate pharmacodynamic and pharmacokinetic parameters after s.c. administration
of two different doses (low dose, 0.2 IU/kg and high dose, 0.4 IU/kg) of insulin
glulisine across healthy subjects in 4 different BMI-classes (lean, overweight,
moderately obese, severely obese), using the euglycemic clamp technique with the
Biostator™.
Secondary objective
- To investigate the pharmacodynamic and pharmacokinetic properties after subcutaneous
administration of insulin glulisine in comparison to insulin lispro and to investigate
the safety and tolerability after subcutaneous administration of insulin glulisine in
comparison to insulin lispro.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
